Important Class Action Notice for Capricor Therapeutics Investors with a Deadline of September 15, 2025
In an important announcement to investors, Levi & Korsinsky, LLP has notified those holding shares in Capricor Therapeutics, Inc. about a forthcoming class action lawsuit. This alert is particularly significant for investors who may have suffered losses due to alleged securities fraud linked to the Company between October 9, 2024, and July 10, 2025. Understanding the details surrounding this case is essential for any affected investors who are considering their options.
The lawsuit generally seeks to recover losses that impacted shareholders during the specified time frame. According to the claims, Capricor's executives provided investors with misleading information regarding their leading cell therapy candidate, deramiocel, which was aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Despite positive statements about the drug's expected success and the potential for a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA), the reality was less optimistic.
On July 11, 2025, the situation took a drastic turn when Capricor disclosed that the FDA issued a Complete Response Letter (CRL), denying their BLA, citing failure to meet statutory requirements for substantial evidence of effectiveness along with a need for additional clinical data. This backlash resulted in a significant drop in Capricor’s stock price, plummeting from $11.40 to $7.64 per share in just one day. This drastic decline has prompted the current lawsuit as investors seek to recover losses incurred due to misleading statements.
Investors interested in participating in the class-action lawsuit must take timely action, as the deadline for appointing lead plaintiffs is set for September 15, 2025. It’s vital to note that even if an investor does not assume the role of lead plaintiff, they still retain the right to recover a portion of any compensation awarded through the class action.
There are no out-of-pocket costs to the investors who qualify as class members, ensuring that those who participate do so without facing financial burden. The law firm of Levi & Korsinsky prides itself on over two decades of legal representation with a strong history of securing considerable monetary relief for affected shareholders. With a dedicated team of over 70 professionals, they are well-equipped to handle the complexities associated with class action cases.
Should you believe you are eligible for this class action or are seeking more details, you are encouraged to reach out to Joseph E. Levi, Esq. at Levi & Korsinsky, LLP via his contact number at (212) 363-7500 or by email. Furthermore, investors can access the detailed submission form pertaining to the case directly through the firm’s website.
The Capricor Therapeutics securities saga underscores the risks associated with investments in biotech firms and the necessity for transparency regarding clinical trial data. As litigation moves forward, it remains crucial for investors to stay informed about the developments of this case and understand their rights regarding potential recoveries.
For thorough oversight of any updates or changes, investors are advised to maintain open lines of communication with their legal counsel and closely monitor official announcements from Levi & Korsinsky as this class action progresses. This will allow them to remain proactive in the pursuit of any compensation they may be entitled to from this complex situation. Furthermore, understanding the implications of the findings during the litigation process may play a critical role in future investment decisions and strategies.
The lawsuit generally seeks to recover losses that impacted shareholders during the specified time frame. According to the claims, Capricor's executives provided investors with misleading information regarding their leading cell therapy candidate, deramiocel, which was aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Despite positive statements about the drug's expected success and the potential for a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA), the reality was less optimistic.
On July 11, 2025, the situation took a drastic turn when Capricor disclosed that the FDA issued a Complete Response Letter (CRL), denying their BLA, citing failure to meet statutory requirements for substantial evidence of effectiveness along with a need for additional clinical data. This backlash resulted in a significant drop in Capricor’s stock price, plummeting from $11.40 to $7.64 per share in just one day. This drastic decline has prompted the current lawsuit as investors seek to recover losses incurred due to misleading statements.
Investors interested in participating in the class-action lawsuit must take timely action, as the deadline for appointing lead plaintiffs is set for September 15, 2025. It’s vital to note that even if an investor does not assume the role of lead plaintiff, they still retain the right to recover a portion of any compensation awarded through the class action.
There are no out-of-pocket costs to the investors who qualify as class members, ensuring that those who participate do so without facing financial burden. The law firm of Levi & Korsinsky prides itself on over two decades of legal representation with a strong history of securing considerable monetary relief for affected shareholders. With a dedicated team of over 70 professionals, they are well-equipped to handle the complexities associated with class action cases.
Should you believe you are eligible for this class action or are seeking more details, you are encouraged to reach out to Joseph E. Levi, Esq. at Levi & Korsinsky, LLP via his contact number at (212) 363-7500 or by email. Furthermore, investors can access the detailed submission form pertaining to the case directly through the firm’s website.
The Capricor Therapeutics securities saga underscores the risks associated with investments in biotech firms and the necessity for transparency regarding clinical trial data. As litigation moves forward, it remains crucial for investors to stay informed about the developments of this case and understand their rights regarding potential recoveries.
For thorough oversight of any updates or changes, investors are advised to maintain open lines of communication with their legal counsel and closely monitor official announcements from Levi & Korsinsky as this class action progresses. This will allow them to remain proactive in the pursuit of any compensation they may be entitled to from this complex situation. Furthermore, understanding the implications of the findings during the litigation process may play a critical role in future investment decisions and strategies.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.